Sign in to fuzzto save your conversations, follow your research and come back anytime.
In the news

Fredun Pharmaceuticals gains 2.84% on Goodman Vetcare stake acquisition

Fredun acquires Furlicks to enter pet wellness market

Fredun Pharma bonus issue today: Last day to buy stock

Fredun Pharma board approves 2:1 bonus issue

Fredun Pharma shares rise 3% on 2:1 bonus issue, strong Q4 results

Kalpataru adds ₹1,250 cr Kandivali redevelopment to pipeline
Company insights, generated from the most recent coverage.
Management has hinted at upcoming acquisitions with zero detail — combined with the 50-OEM launch plan and PIC/s upgrades, inorganic adds are an unfunded option on the model, not a base-case driver.
FII holding cut to 0.69% from 1.06% while DII rose to 3.44% — foreign money is exiting this small cap and domestic institutions are the marginal buyer, which changes who has to be convinced at a 48x P/E.
FY26 borrowings of Rs 56.31 Cr against equity of Rs 278.11 Cr imply debt/equity of ~0.20x, not the 0.93x shown in ratio screens — the screen figure is overstated, so the leverage risk flagged on Fredun is far smaller than it looks.